Khan, Mohd Wajid A., Chen, Hung, Eberl, Matthias and Moser, Bernhard ORCID: https://orcid.org/0000-0002-4354-4572 2014. In vitro expanded γδ T-APC: revelance for cancer immunotherapy [Abstract]. Human Gene Therapy 25 (5) , A15-A15. 10.1089/hum.2014.2509.abstracts |
Abstract
Immunotherapy is a fast advancing methodology involving one of two approaches: (1) compounds targeting immune checkpoints and (2) cellular immunomodulators. The latter approach is still largely experimental and features in vitro generated, live immune effector cells, or antigen-presenting cells. γδ T cells are known for their efficient in vitro tumor killing activities. Consequently, many laboratories worldwide are currently testing the tumor killing function of γδ T cells in clinical trials. Reported benefits are modest; however, these studies have demonstrated that large γδ T-cell infusions were well tolerated. Here, we discuss the potential of using human γδ T cells not as effector cells but as a novel cellular vaccine for treatment of cancer patients. Antigen-presenting γδ T cells do not require to home to tumor tissues but, instead, need to interact with endogenous, tumor-specific αβ T cells in secondary lymphoid tissues. Newly mobilized effector αβ T cells are then thought to overcome the immune blockade by creating proinflammatory conditions fit for effector T-cell homing to and killing of tumor cells. Immunotherapy may include tumor antigen-loaded γδ T cells alone or in combination with immune checkpoint inhibitors.
Item Type: | Article |
---|---|
Date Type: | Publication |
Status: | Published |
Schools: | Medicine Systems Immunity Research Institute (SIURI) |
Subjects: | Q Science > QR Microbiology > QR180 Immunology R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) |
Publisher: | Mary Ann Liebert |
ISSN: | 1043-0342 |
Related URLs: | |
Last Modified: | 28 Oct 2022 09:20 |
URI: | https://orca.cardiff.ac.uk/id/eprint/74156 |
Actions (repository staff only)
Edit Item |